Autor: |
Lenka N.C. Boyd, Mahsoem Ali, Mariska M.G. Leeflang, Giorgio Treglia, Ralph de Vries, Tessa Y.S. Le Large, Marc G. Besselink, Elisa Giovannetti, Hanneke W.M. van Laarhoven, Geert Kazemier |
Jazyk: |
angličtina |
Rok vydání: |
2023 |
Předmět: |
|
Zdroj: |
EClinicalMedicine, Vol 55, Iss , Pp 101747- (2023) |
Druh dokumentu: |
article |
ISSN: |
2589-5370 |
DOI: |
10.1016/j.eclinm.2022.101747 |
Popis: |
Summary: Background: Novel blood-based protein biomarkers may be of value for efficient, accurate, and non-invasive diagnosis of pancreatic cancer. This study assesses the diagnostic accuracy of newly recognized blood-based protein biomarkers for detecting pancreatic cancer, and investigates their added value to CA19-9, the common blood-based biomarker in clinical use for pancreatic cancer. Methods: PubMed, Embase, Web of Science, and the Wiley/Cochrane Library were systematically searched from inception until June 2022. A meta-analysis of aggregate and individual participant data was conducted using frequentist and Bayesian hierarchical random-effects models. The added clinical utility of protein biomarkers was investigated using bootstrap bias-corrected decision curve analyses. Findings: Aggregate data from 28 primary studies (6127 participants) were included, of which 8 studies (1790 participants) provided individual participant data. CA19-9 was significantly more accurate than MIC-1 for distinguishing pancreatic cancer from benign disease (AUC, 0.83 vs 0.74; relative diagnostic odds ratio [rDOR], 2.10 [95% CI, 0.98–4.48]; p = 0.002), THBS2 (AUC, 0.87 vs 0.69; rDOR, 4.53 [2.16–9.39]; p |
Databáze: |
Directory of Open Access Journals |
Externí odkaz: |
|